{"id":2066258,"date":"2026-07-21T13:00:39","date_gmt":"2026-07-21T11:00:39","guid":{"rendered":"https:\/\/www.luxsure.fr\/2026\/07\/21\/ai-doesnt-just-shorten-the-drug-development-process-it-shifts-the-burden-of-proof\/"},"modified":"2026-07-21T13:06:19","modified_gmt":"2026-07-21T11:06:19","slug":"ai-doesnt-just-shorten-the-drug-development-process-it-shifts-the-burden-of-proof","status":"publish","type":"post","link":"https:\/\/www.luxsure.fr\/en\/2026\/07\/21\/ai-doesnt-just-shorten-the-drug-development-process-it-shifts-the-burden-of-proof\/","title":{"rendered":"AI doesn’t just shorten the drug development process. It shifts the burden of proof."},"content":{"rendered":"\n

For a long time, the pharmaceutical industry has been one of the last areas where slowness served as a safeguard. Artificial intelligence, quantum simulation, and synthetic biology now promise to shorten cycles that used to stretch over ten to fifteen years. But the real question isn\u2019t speed. It\u2019s what we\u2019re willing to accept as sufficiently proven. <\/p>\n\n

In the pharmaceutical industry, AI is no longer just a hypothetical concept. It is used in target identification, molecule design, the optimization of clinical trials, the drafting of regulatory reports, manufacturing, and even the allocation of commercial resources. Certain documentation tasks that used to take several months can now be completed in weeks, or sometimes even days. For small molecules, the use of AI has become sufficiently established that it is no longer considered a marginal experiment. <\/p>\n\n

Confusion often stems from a misunderstanding. AI applied to medicine does not always resemble the large language models that dominate the public imagination. It is frequently based on specialized models, trained not on sentences but on molecular structures, trial results, and laboratory data. In the case of new antibiotics, these models can learn to identify or generate molecules capable of targeting difficult-to-treat bacteria, with greater potency and reduced toxicity. <\/p>\n\n

But the elegance of the model is not enough. Biology remains a discipline that resists easy solutions. A predicted molecule must be tested. A hypothesis must be put to the test in the lab. And the faster AI makes predictions, the more the experimental system becomes the new point of friction. <\/p>\n\n

The lab becomes the arbiter<\/h2>\n\n

For a long time, AI was an analytical tool: biologists produced data, and experts interpreted it. Now the tables have turned. Models now generate hypotheses, suggest molecules, and guide the design of experiments. The machine does not replace the laboratory; rather, it relies on it more than ever. <\/p>\n\n

This shift is significant. The bottleneck is no longer just computation, but the ability to produce reliable, diverse, and actionable data. Models improve as the quality of their data improves. In some cases, simply adding more data is no longer enough: we need to conduct different, more diverse experiments\u2014ones that are sometimes more expensive but more informative. <\/p>\n\n

The industry is thus discovering a simple truth: AI strategy is becoming data strategy. Without data ready for AI, there can be no useful AI. This requires precise governance: identified data owners, clear responsibilities, and common standards across research, development, manufacturing, and compliance. In an industry where data processing must span multiple countries, regulatory frameworks, and supply chains, architecture matters just as much as the algorithm. <\/p>\n\n

Details<\/h2>\n\n

A clinical report can take about six months to produce using a traditional process. With AI, certain documentation steps can be reduced to a few weeks or a few days. This is not a scientific shortcut; it is an administrative streamlining. This distinction is essential. <\/p>\n\n

Negative data: that invisible luxury<\/h2>\n\n

One of the most underestimated aspects concerns failures. Pharmaceutical databases naturally highlight successes: promising molecules, conclusive trials, validated properties. Yet a model also learns from what doesn\u2019t work. A dataset composed almost entirely of successes can bias the algorithm and prevent it from understanding the limitations of a chemical space. <\/p>\n\n

In the field of drug development, failure provides valuable information. It points to an area to avoid, a toxicity issue, a biological dead end, or a false lead. Yet this data is rarely shared. The reasons are well known: intellectual property, a culture of secrecy, competition among stakeholders, and the fear of revealing a molecular structure or strategic direction. <\/p>\n\n

This is where a new tension is emerging. Commercial value remains tied to patentable molecules, but intermediate data\u2014which may not be directly owned\u2014could contribute to scientific commons. Toxicity tests, negative results, and standardized measurements could become a shared foundation without necessarily threatening competitive advantage. To truly accelerate progress, we may need to learn to share what, until recently, remained locked away in drawers. <\/p>\n\n

Quantum computing: a promising field\u2014as long as we remain modest<\/h2>\n\n

Quantum simulation enters this landscape with a unique promise: to better describe certain complex molecular phenomena. In theory, it could generate more accurate training data for AI models, particularly for problems where classical methods reach their limits. <\/p>\n\n

But we must keep a clear perspective. The integration of quantum computing into major pharmaceutical companies is not imminent. The machines exist, and experiments are already yielding consistent results, but not yet at the scale, speed, and robustness required by the industry. The most plausible role, in the short term, is not to replace current methods, but to enhance specific aspects of the pipelines: targeted calculations, validation of subsets, and the generation of more granular data. <\/p>\n\n

The real advantage of quantum computing, for now, may not be its immediate performance. It lies in the groundwork: identifying problems where classical methods fall short, designing architectures capable of integrating quantum data in the future, and avoiding the need to rebuild the entire system once the technology matures. <\/p>\n\n

Pick up the pace without confusing speed with proof<\/h2>\n\n

It would be tempting to paint a picture of medicine in which AI designs treatments, the lab confirms them, and patients benefit almost immediately. The reality is more complex. Between a molecule generated by a model and an available treatment, there are still clinical trials, toxicity testing, manufacturing, regulatory approval, access, pricing, and trust to consider. <\/p>\n\n

This is where modernizing the evaluation process becomes crucial. Authorities cannot treat AI as a mere decorative \u201cblack box,\u201d but neither can they ignore its ability to reduce certain processing times. The issue is not to slow down innovation out of caution, nor to accelerate it out of fascination. It is to distinguish between what falls under decision support, document automation, molecular design, or clinical evidence. <\/p>\n\n

In five years, there could be more treatments developed through partially generative processes. The tailored design of molecules, guided by specific indications and actual patient needs, could become more viable. Patients themselves will undoubtedly play a more active role\u2014better informed, more involved, and sometimes even serving as driving forces in programs related to rare or underserved diseases. <\/p>\n\n

But one thing will remain constant: a drug is not an interface. It enters the body. There, it encounters a complexity that even the most sophisticated models cannot circumvent. AI can speed up the formulation of a hypothesis. It can expand the realm of possibilities. It can save months of writing and coordination. But it does not eliminate the need to prove a point. <\/p>\n\n

Speed, then, is not the opposite of safety. It becomes the test of safety. The faster the industry can produce, the more precisely it will have to demonstrate what has been accelerated, what has been verified, and what remains uncertain. This may be where the future of medicine lies: not in the promise of moving faster, but in the art of making that speed trustworthy. <\/p>\n\n

\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

For a long time, the pharmaceutical industry has been one of the last areas where slowness served as a safeguard. Artificial intelligence, quantum simulation, and synthetic biology now promise to…<\/p>\n","protected":false},"author":2,"featured_media":2063614,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[77972],"tags":[79507,79508,79509,79512,79511,79510],"class_list":["post-2066258","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-luxury-and-ai","tag-ai-in-drug-development","tag-clinical-trials","tag-drug-discovery","tag-health-data","tag-pharmaceutical-ai","tag-quantum-simulation"],"_links":{"self":[{"href":"https:\/\/www.luxsure.fr\/en\/wp-json\/wp\/v2\/posts\/2066258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.luxsure.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.luxsure.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.luxsure.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.luxsure.fr\/en\/wp-json\/wp\/v2\/comments?post=2066258"}],"version-history":[{"count":0,"href":"https:\/\/www.luxsure.fr\/en\/wp-json\/wp\/v2\/posts\/2066258\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.luxsure.fr\/en\/wp-json\/wp\/v2\/media\/2063614"}],"wp:attachment":[{"href":"https:\/\/www.luxsure.fr\/en\/wp-json\/wp\/v2\/media?parent=2066258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.luxsure.fr\/en\/wp-json\/wp\/v2\/categories?post=2066258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.luxsure.fr\/en\/wp-json\/wp\/v2\/tags?post=2066258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}